Search
Mito-4509
go.drugbank.com/drugs/DB05846ExperimentalMito-4509 is a non-feminizing estrogen analog that could affect mitochondrial metabolic pathways. It is used to treat Parkinson's Disease, Alzheimer's Disease, Retinal Disorders and other neurologic Disorders.
UCB-1184197
go.drugbank.com/drugs/DB05092Investigational(now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis.
Cintredekin besudotox
go.drugbank.com/drugs/DB05305InvestigationalCintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual
Tepoxalin
go.drugbank.com/drugs/DB11466ExperimentalVet approvedTepoxalin is a nonsteroidal anti-inflammatory drug approved for veterinary use in the United States and many other countries.
Uprifosbuvir
go.drugbank.com/drugs/DB15206InvestigationalUprifosbuvir is under investigation in clinical trial NCT02332707 (Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis
Hu-rhEGF-rP64k/Mont
go.drugbank.com/drugs/DB15781InvestigationalHu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically conjugated to recombinant P64K (rP64K)) and an adjuvant (Montanide ISA51VG) being investigated for
Escin
go.drugbank.com/drugs/DB15907InvestigationalSodium aescinate is under investigation in clinical trials for its potential to treat cerebral conditions, including NCT04247659 (studying the relationship between asymmetric vascular sign of cortex and
BBM-H803
go.drugbank.com/drugs/DB17700InvestigationalBBM-H803 is a recombinant adeno-associated virus (AAV) based gene therapy drug for hemophilia A developed and manufactured by Belief BioMed.
SIG-007
go.drugbank.com/drugs/DB17710ExperimentalDeveloped by Sigilon Therapeutics, t is being investigated for the treatment of Fabry Disease.[L46153]
Muvalaplin
go.drugbank.com/drugs/DB21568InvestigationalMuvalaplin is under investigation in clinical trial NCT05563246 (A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events).